These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 32325200

  • 1. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
    Kresken M, Körber-Irrgang B, Korte-Berwanger M, Pfennigwerth N, Gatermann SG, Seifert H, German Carbapenem Resistance Study Group.
    Int J Antimicrob Agents; 2020 Jun; 55(6):105959. PubMed ID: 32325200
    [Abstract] [Full Text] [Related]

  • 2. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021.
    Lee YL, Ko WC, Hsueh PR.
    Int J Antimicrob Agents; 2023 Aug; 62(2):106867. PubMed ID: 37244423
    [Abstract] [Full Text] [Related]

  • 3. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
    Wi YM, Greenwood-Quaintance KE, Schuetz AN, Ko KS, Peck KR, Song JH, Patel R.
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29133568
    [Abstract] [Full Text] [Related]

  • 4. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM, Aktaþ E, Alfouzan W, Bourassa L, Brink A, Burnham CD, Canton R, Carmeli Y, Falcone M, Kiffer C, Marchese A, Martinez O, Pournaras S, Satlin M, Seifert H, Thabit AK, Thomson KS, Villegas MV, Nicolau DP, ERACE-PA Global Study Group.
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2533-2541. PubMed ID: 34291323
    [Abstract] [Full Text] [Related]

  • 5. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
    O'Neall D, Juhász E, Tóth Á, Urbán E, Szabó J, Melegh S, Katona K, Kristóf K.
    Acta Microbiol Immunol Hung; 2020 Mar 26; 67(1):61-65. PubMed ID: 32208923
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Susceptibility of Multidrug-Resistant Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from Germany to Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Imipenem-Relebactam.
    Kresken M, Wohlfarth E, Wichelhaus TA, Gatermann SG, Pfennigwerth N, Eisfeld J, Seifert H, German BL/BLI Study Group.
    Microb Drug Resist; 2023 Apr 26; 29(4):138-144. PubMed ID: 36622756
    [Abstract] [Full Text] [Related]

  • 9. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF, Liu CP, Wang NY, Shih SC.
    BMC Infect Dis; 2016 Aug 24; 16(1):444. PubMed ID: 27553962
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020.
    Karlowsky JA, Lob SH, Siddiqui F, Akrich B, DeRyke CA, Young K, Motyl MR, Hawser SP, Sahm DF.
    J Med Microbiol; 2023 Feb 24; 72(2):. PubMed ID: 36763081
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial Susceptibility Profiles To Predict the Presence of Carbapenemase Genes among Carbapenem-Resistant Pseudomonas aeruginosa Isolates.
    Vallabhaneni S, Huang JY, Grass JE, Bhatnagar A, Sabour S, Lutgring JD, Campbell D, Karlsson M, Kallen AJ, Nazarian E, Snavely EA, Morris S, Wang C, Lee R, Koag M, Lewis R, Garcia B, EIP Work Group, Brown AC, Walters MS.
    J Clin Microbiol; 2021 May 19; 59(6):. PubMed ID: 33762362
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
    Mirza HC, Hortaç E, Koçak AA, Demirkaya MH, Yayla B, Güçlü AÜ, Başustaoğlu A.
    J Glob Antimicrob Resist; 2020 Mar 19; 20():334-338. PubMed ID: 31568882
    [Abstract] [Full Text] [Related]

  • 14. Genomic Surveillance of Clinical Pseudomonas aeruginosa Isolates Reveals an Additive Effect of Carbapenemase Production on Carbapenem Resistance.
    Diorio-Toth L, Irum S, Potter RF, Wallace MA, Arslan M, Munir T, Andleeb S, Burnham CD, Dantas G.
    Microbiol Spectr; 2022 Jun 29; 10(3):e0076622. PubMed ID: 35638817
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK.
    Int J Antimicrob Agents; 2018 Feb 29; 51(2):181-189. PubMed ID: 28993143
    [Abstract] [Full Text] [Related]

  • 17. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
    Giani T, Arena F, Pollini S, Di Pilato V, D'Andrea MM, Henrici De Angelis L, Bassetti M, Rossolini GM, Pseudomonas aeruginosa Working Group.
    J Antimicrob Chemother; 2018 Mar 01; 73(3):664-671. PubMed ID: 29216350
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance.
    Kayama S, Kawakami S, Kondo K, Kitamura N, Yu L, Hayashi W, Yahara K, Sugawara Y, Sugai M.
    J Glob Antimicrob Resist; 2024 Sep 01; 38():12-20. PubMed ID: 38789082
    [Abstract] [Full Text] [Related]

  • 20. Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020.
    Karlowsky JA, Lob SH, Khan TK, Chen WT, Woo PCY, Seto WH, Ip M, Leung SWM, Wong QW, Chau RWY, DeRyke CA, Young K, Motyl MR, Sahm DF.
    J Glob Antimicrob Resist; 2023 Jun 01; 33():260-266. PubMed ID: 37086892
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.